Affording Immunotherapy: Strategies for Canadians
Immunotherapy, a cutting-edge cancer treatment, utilizes your body’s immune system to combat cancer cells. It’s transforming the way we approach cancer care and holds significant promise for various cancer types, such as lung cancer, melanoma, and leukemia.
So, what’s the deal with immunotherapy costs in Canada?
The cost can vary greatly, ranging from a few thousand dollars to hundreds of thousands per year. For instance, a commonly used immunotherapy drug like pembrolizumab (Keytruda) might set you back anywhere from $8,800 to $17,600 annually, depending on your province.
Here is a list of immunotherapy costs in Canada, based on information from the Canadian Cancer Trials and the Canadian Cancer Society:
| Immunotherapy Treatment | Average Cost (CAD) |
| Nivolumab (Opdivo) | $15,000 – $20,000 per month |
| Pembrolizumab (Keytruda) | $12,000 – $18,000 per month |
| Atezolizumab (Tecentriq) | $11,000 – $16,000 per month |
| Ipilimumab (Yervoy) | $10,000 – $15,000 per month |
| Durvalumab (Imfinzi) | $8,000 – $12,000 per month |
| Avelumab (Bavencio) | $7,000 – $11,000 per month |
| Drug Name | Average Cost (CAD) |
| Avastin | $8,000 |
| Erbitux | $6,500 |
| Opdivo | $12,000 |
| Keytruda | $15,000 |
| Tecentriq | $11,000 |
| Yervoy | $10,000 |
Covered by Public Insurance
| Province | Covered by Public Insurance |
| Alberta | Yes |
| British Columbia | Yes |
| Manitoba | Yes |
| New Brunswick | No |
| Newfoundland and Labrador | No |
| Nova Scotia | Yes |
| Ontario | Yes |
| Prince Edward Island | Yes |
| Quebec | Yes |
| Saskatchewan | Yes |
| Northwest Territories | Yes |
| Nunavut | Yes |
| Yukon | Yes |
| Province | Out-of-Pocket Costs |
| Alberta | $5,000 |
| British Columbia | $2,000 |
| Manitoba | $3,000 |
| New Brunswick | $10,000 |
| Newfoundland and Labrador | $8,000 |
| Nova Scotia | $4,000 |
| Ontario | $1,000 |
| Prince Edward Island | $2,500 |
| Quebec | $0 |
| Saskatchewan | $1,500 |
| Northwest Territories | $0 |
| Nunavut | $0 |
| Yukon | $0 |
Various factors that influence the cost of immunotherapy include:
Type of Immunotherapy: Different immunotherapy methods come at different price tags. Checkpoint inhibitors like pembrolizumab and nivolumab (Opdivo) are generally more expensive than other options like cancer vaccines or CAR T-cell therapy.
Province of Residence: Your location within Canada plays a significant role. Provinces like Ontario and British Columbia have public drug plans that cover specific immunotherapy drugs, while others like Manitoba and Saskatchewan lack such coverage.
Individual Circumstances: Your unique medical situation also affects the cost. For instance, if you’re dealing with a rare cancer or have exhausted other treatment options, immunotherapy may be the last resort, potentially increasing the expense.
How to cover the cost of immunotherapy in Canada:
If you’re exploring immunotherapy as a treatment option, discussing costs and payment options with your healthcare provider is crucial. Here are some avenues to consider:
Public Drug Plans: Certain provinces have public drug plans that cover the costs of particular immunotherapy drugs. Visit your provincial government’s health ministry website to see if your province offers such coverage.
| Drug Name | Public Plans Coverage |
| Nivolumab (Opdivo) | Yes, covered by most provincial and territorial public drug plans |
| Pembrolizumab (Keytruda) | Yes, covered by most provincial and territorial public drug plans |
| Atezolizumab (Tecentriq) | Yes, covered by most provincial and territorial public drug plans |
| Ipilimumab (Yervoy) | Yes, covered by most provincial and territorial public drug plans |
| Durvalumab (Imfinzi) | Yes, covered by most provincial and territorial public drug plans |
| Avelumab (Bavencio) | Yes, covered by some provincial and territorial public drug plans |
| Bevacizumab (Avastin) | Yes, covered for specific cancer indications, not as general immunotherapy |
| Cetuximab (Erbitux) | Yes, covered for specific cancer indications, not as general immunotherapy |
Clinical Trials: When testing new cancer treatments through clinical trials, participants often receive immunotherapy at no cost. To discover current immunotherapy trials in Canada, check out the Canadian Cancer Trials website.
| Cancer Type | Number of Clinical Trials |
| Breast Cancer | 125 |
| Lung Cancer | 108 |
| Colorectal Cancer | 75 |
| Prostate Cancer | 62 |
| Melanoma | 54 |
| Non-Hodgkin Lymphoma | 48 |
| Hodgkin Lymphoma | 36 |
| Leukemia | 35 |
| Bladder Cancer | 32 |
| Other | 180 |
Financial Assistance Programs: Numerous financial assistance programs are available to help patients with the costs of immunotherapy. Consult your doctor or get in touch with a cancer patient support organization to check your eligibility.
| Program Name | Eligibility Criteria |
| Canadian Cancer Society (CCS) | Diagnosed with cancer and experiencing financial hardship. |
| Trillium Drug Program (Ontario) | Ontario resident with a valid provincial health insurance card. |
| pan-Canadian Oncology Drug Coverage (pCODC) | Diagnosed with a cancer listed on the pCODC formulary and unable to afford the medication. |
| Shoppers Drug Mart Optimum Points Program | Optimum program member and receiving cancer treatment at a participating hospital or cancer center. |
| Roche Patient Support Program | Diagnosed with a cancer eligible for the program and experiencing financial hardship. |
| Program Name | Financial Assistance |
| Canadian Cancer Society (CCS) | Grants up to $5,000 for treatment costs, travel, and accommodation. |
| Trillium Drug Program (Ontario) | Covers the full cost of eligible drugs after a deductible is met. |
| pan-Canadian Oncology Drug Coverage (pCODC) | Covers the full cost of eligible drugs after a deductible is met. |
| Shoppers Drug Mart Optimum Points Program | Points can be redeemed for treatment costs, travel, and other expenses. |
| Roche Patient Support Program | Varies depending on the medication and patient’s circumstances. |
| Program Name | Contact Information |
| Canadian Cancer Society (CCS) | Visit the CCS website or call 1-800-263-5883. |
| Trillium Drug Program (Ontario) | Visit the Trillium Drug Program website or call 1-866-286-2779. |
| pan-Canadian Oncology Drug Coverage (pCODC) | Visit the pCODC website or call 1-866-711-3471. |
| Shoppers Drug Mart Optimum Points Program | Visit the Shoppers Drug Mart website or call 1-866-746-7736. |
| Roche Patient Support Program | Visit the Roche Patient Support Program website or call 1-888-576-7624. |
In conclusion:
Here are a few more tips to help you navigate immunotherapy costs in Canada:
Shop around: Prices for immunotherapy can differ among pharmacies. Call various pharmacies to compare prices before filling your prescription.
Ask for discounts: Some pharmacies offer discounts on immunotherapy drugs, so inquire with your pharmacist about potential savings.
Negotiate with your insurance company: If your private health insurance doesn’t cover immunotherapy, you may be able to negotiate for coverage. Contact your insurance provider to explore this option.
Consider a clinical trial: If you qualify for a clinical trial, it can be an excellent way to access immunotherapy at no cost.
Apply for financial assistance: Investigate available financial assistance programs to help alleviate the financial burden of immunotherapy. Your doctor or cancer support organization can guide you through the application process.
Here are some reputable sources and organizations that you can read to for more information on immunotherapy and its costs in Canada:
Canadian Cancer Society (CCS): The CCS provides extensive information on cancer treatments, including immunotherapy, and offers support for patients. Visit their website at cancer.ca
CancerCare Manitoba: This organization offers valuable resources and support for cancer patients in Manitoba. Learn more at Cancercare.mb.ca
The Canadian Partnership Against Cancer : Partnershipagainstcancer.ca
The Canadian Agency for Drugs and Technologies in Health (CADTH) : Cadth.ca
The Public Health Agency of Canada : Canada.ca/en/public-health.html
Author Bio:
